Regeneron Pharmaceuticals (REGN) Position Lifted by Lagoda Investment Management Lp

Marco Green
April 17, 2018

Steward Partners Investment Advisory LLC now owns 369 shares of the biopharmaceutical company's stock worth $138,000 after purchasing an additional 307 shares during the period. Cwm Ltd Co holds 0% of its portfolio in Eli Lilly and Company (NYSE:LLY) for 1,248 shares. UBS Asset Management Americas Inc. now owns 553,501 shares of the biopharmaceutical company's stock worth $208,094,000 after purchasing an additional 267,442 shares during the period. 846,108 shares of the company traded hands, compared to its average volume of 792,429.

Regeneron (NASDAQ:REGN) last issued its earnings results on Thursday, February 8th. It has underperformed by 25.74% the S&P500.

Ron Gutfleish increased its stake in Popular Inc (BPOP) by 11.02% based on its latest 2017Q4 regulatory filing with the SEC. Moreover, Welch & Forbes Lc has 0.33% invested in Eli Lilly and Company (NYSE:LLY) for 145,968 shares. (NASDAQ:REGN). Rampart Management Ltd Company invested in 0.14% or 941 shs. Verizon Communications now has $196.74B valuation. The stock increased 0.22% or $0.48 during the last trading session, reaching $218.89. The shares were sold at an average price of $340.00, for a total value of $680,000.00. It has underperformed by 11.55% the S&P500. Regeneron Pharmaceuticals has a 1-year low of $325.35 and a 1-year high of $452.96. "Buy" rating has 6, "Sell" are 1, while 12 are "Hold". Therefore 32% are positive. On Friday, October 20 the stock of Regeneron Pharmaceuticals, Inc. On Thursday, November 9 the stock rating was maintained by Morgan Stanley with "Equal-Weight". BMO Capital Markets maintained the stock with "Hold" rating in Tuesday, July 18 report. Harding Loevner LP stated it has 1.35% of its capital in Regeneron Pharmaceuticals, Inc. Jefferies Group reissued a "hold" rating and set a $421.00 price objective on shares of Regeneron in a report on Friday, February 2nd. The rating was maintained by Jefferies with "Sell" on Tuesday, June 13. As per Wednesday, August 16, the company rating was initiated by Evercore. On Thursday, January 25 the stock rating was maintained by Robert W. Baird with "Buy". The rating was upgraded by Credit Suisse to "Outperform" on Tuesday, December 20.

During 2017 Q4 the big money sentiment is 1.17. Its the same as in 2017Q3.

Xact Kapitalforvaltning AB raised its stake in shares of Regeneron (NASDAQ:REGN) by 23.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. 4 are held by Lazard Asset Limited.

Regeneron Pharmaceuticals, Inc. registered $1.71 million net activity with 0 insider buys and 3 insider sales since February 9, 2018. Chesley Taft And Assoc Limited Liability reported 0.15% of its portfolio in Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has declined 14.19% since April 14, 2017 and is downtrending. (NASDAQ:REGN) for 116,830 shares. Mitsubishi Ufj Trust & Banking stated it has 0.1% of its capital in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Two Sigma Limited Co invested in 0.01% or 905 shs. Guggenheim maintained Regeneron Pharmaceuticals, Inc.

Cornercap Investment Counsel Inc, which manages about $912.27M and $729.53 million US Long portfolio, decreased its stake in Gilead Sciences Inc Com (NASDAQ:GILD) by 55,959 shares to 2,891 shares, valued at $208,000 in 2017Q4, according to the filing. (NASDAQ:REGN) for 6,027 shs.

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. (NASDAQ:REGN). Stratos Wealth Partners invested 0% of its portfolio in Regeneron Pharmaceuticals, Inc. REGN's total short interest was 1.94M shares in April as published by FINRA. Oppenheimer Asset Mgmt reported 10,609 shares. John G Ullman & Associate has 900 shares.

Since February 9, 2018, it had 0 buys, and 3 selling transactions for $1.71 million activity.

Among 29 analysts covering Verizon Communications Inc. Therefore 64% are positive.

REGN has been the topic of a number of recent analyst reports. The stock has "Sell" rating by BMO Capital Markets on Monday, June 5. On Friday, February 9 the firm earned "Outperform" rating by Leerink Swann. The stock of Verizon Communications Inc. J.P. Morgan maintained the stock with "Hold" rating in Monday, August 14 report. Goldman Sachs upgraded the shares of BPOP in report on Monday, July 27 to "Buy" rating. The company was maintained on Wednesday, December 6 by SunTrust. The firm has "Neutral" rating given on Wednesday, January 24 by JP Morgan. (NASDAQ:REGN) on Thursday, November 9 with "Market Perform" rating.

Investors sentiment is 1.03 in Q4 2017. Its up 0.14, from 0.88 in 2017Q3. It improved, as 42 investors sold LLY shares while 380 reduced holdings. 191 grew positions while only 71 funds amassed positions. The SI to X RAIL ENTERTAINMENT INC's float is 0.04%. (NYSE:VZ) for 78,317 shares. (NYSE:VZ) for 491,965 shares. Invesco Limited invested in 0.13% or 962,895 shares. Tompkins Fin reported 0.94% in Verizon Communications Inc. Also, Director Joseph L. Goldstein sold 1,000 shares of the company's stock in a transaction that occurred on Friday, February 9th. 608,878 were accumulated by Fincl Counselors. (NASDAQ:BPOP). Ohio-based Diamond Hill Capital has invested 0.78% in Popular, Inc. Exxonmobil Inv Mngmt Tx has 12,249 shares for 0.13% of their portfolio. Legacy Capital Prns has invested 2.21% in Verizon Communications Inc. Conning reported 0.07% of its portfolio in Eli Lilly and Company (NYSE:LLY). Calamos Advsr Ltd owns 120,266 shares or 0.23% of their USA portfolio. Hedge funds and other institutional investors own 66.40% of the company's stock. Hudock Capital Gp Lc owns 90 shares. Vanguard Growth Etf (VUG) was raised too.

Analysts await Microsoft Corporation (NASDAQ:MSFT) to report earnings on April, 26. They expect $5.08 EPS, up 135.19 % or $2.92 from last year's $2.16 per share.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER